Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response

BACKGROUND: Minimally invasive radiofrequency ablation (RFA) is used as a first-line treatment option for hepatocellular cancer (HCC) with the weaknesses of incomplete ablation, tumor recurrence, and inferior outcomes. To overcome this limitation, we proposed to develop sunitinib-RFA integrated ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Xiaoqiang, Yang, Ming, Ma, Lixin, Sauer, Madeline, Avella, Diego, Kaifi, Jussuf T, Bryan, Jeffrey, Cheng, Kun, Staveley-O’Carroll, Kevin F, Kimchi, Eric T, Li, Guangfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594543/
https://www.ncbi.nlm.nih.gov/pubmed/33115942
http://dx.doi.org/10.1136/jitc-2020-001038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594543/
https://www.ncbi.nlm.nih.gov/pubmed/33115942
http://dx.doi.org/10.1136/jitc-2020-001038

Ejemplares similares